FDA con­verts Pfiz­er's Tiv­dak to full ap­proval in cer­vi­cal can­cer

Pfiz­er’s new cer­vi­cal can­cer drug Tiv­dak has been con­vert­ed from an ac­cel­er­at­ed to a full ap­proval.

The Seagen and Gen­mab-parterned drug, al­so known as ti­so­tum­ab ve­dotin-tftv, was first ap­proved via the FDA’s ac­cel­er­at­ed path­way in Sep­tem­ber 2021. It’s now in Pfiz­er’s port­fo­lio, fol­low­ing the New York phar­ma gi­ant’s $43 bil­lion ac­qui­si­tion of Seagen at the end of last year.

The full ap­proval was based on an open-la­bel study show­ing that Tiv­dak pa­tients saw a me­di­an over­all sur­vival of 11.5 months com­pared to 9.5 months for pa­tients who re­ceived on­ly chemother­a­py (p=0.0038). Me­di­an pro­gres­sion-free sur­vival in the Tiv­dak arm was 4.2 months, com­pared to 2 months in the chemother­a­py arm. Tiv­dak gen­er­at­ed $64 mil­lion in sales for Seagen over the first nine months of 2023, be­fore the com­pa­ny was ac­quired by Pfiz­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER